Corcept Therapeutics has received a complete response letter from the FDA for its new drug application for relacorilant, a treatment for hypertension caused by hypercortisolism.
In the Dec. 31 letter, the FDA acknowledged that Corcept’s GRACE trial met its primary endpoint and that its GRADIENT trial provided supporting evidence; however, additional data is needed to support a favorable benefit-risk assessment, the agency said.
Relacorilant is a selective glucocorticoid receptor antagonist that modulates cortisol activity. The drug has received orphan drug designation in both the U.S. and Europe for the treatment of hypercortisolism.
The FDA has set a separate Prescription Drug User Fee Act action date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
